Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. NSCLC, previously treated with immunotherapy, chemotherapy, and KRASG12C (OFF) inhibitors
    2. NSCLC, previously treated with immunotherapy and chemotherapy, naïve to KRASG12C (OFF) inhibitors
    3. Solid tumors, previously treated, na

You may not be eligible for this study if the following are true:

    1. Primary CNS tumor(s)
    2. Untreated brain or leptomeningeal metastases
    3. History of interstitial lung disease (ILD) requiring treatment with glucocorticoids, history of noninfectious pneumonitis requiring glucocorticoids, or any act

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.